Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours by Veeck, Jürgen et al.
Open Access
Available online http://breast-cancer-research.com/content/10/5/R82
Page 1 of 11
(page number not for citation purposes)
Vol 10 No 5 Research article
Wnt signalling in human breast cancer: expression of the putative 
Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by 
promoter hypermethylation in mammary tumours
Jürgen Veeck1, Nuran Bektas1, Arndt Hartmann2, Glen Kristiansen3, Uwe Heindrichs4,5, 
Ruth Knüchel1 and Edgar Dahl1
1Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH, Aachen, Pauwelsstrasse 30, D-52074 Aachen, Germany
2Department of Pathology, University of Erlangen, Krankenhausstrasse 12, D-91054 Erlangen, Germany
3Institute of Surgical Pathology, University Hospital Zürich, Schmelzbergstrasse 12, CH-8091 Zürich, Switzerland
4Department of Gynecology, Breast Surgery and Mastology, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen, 
Germany
5Brustzentrum Aachen-Stadt, Pauwelsstrasse 30, D-52074 Aachen, Germany
Corresponding author: Edgar Dahl, edahl@ukaachen.de
Received: 29 May 2008 Revisions requested: 25 Jun 2008 Revisions received: 2 Sep 2008 Accepted: 30 Sep 2008 Published: 30 Sep 2008
Breast Cancer Research 2008, 10:R82 (doi:10.1186/bcr2151)
This article is online at: http://breast-cancer-research.com/content/10/5/R82
© 2008 Veeck et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Expression of the putative Wnt signalling inhibitor
Dickkopf-3 (DKK3) is frequently lost in human cancer tissues
because of aberrant 5'-cytosine methylation within the DKK3
gene promoter. Since other Wnt signalling inhibitors have been
reported to be targets of epigenetic inactivation in human breast
cancer, we questioned if DKK3 expression is also epigenetically
silenced during breast carcinogenesis and therefore might
contribute to oncogenic Wnt signalling commonly found in this
disease.
Methods  DKK3  mRNA expression and DKK3  promoter
methylation were determined by RT-PCR, realtime PCR and
methylation-specific PCR in breast cell lines (n = 9), normal
breast tissues (n = 19) and primary breast carcinomas (n =
150), respectively. In vitro DNA demethylation was performed
by incubating breast cell lines with 5-aza-2'-deoxycytidine and
trichostatin A. DKK3 protein expression was analysed by
immunohistochemistry in breast carcinomas (n = 16) and
normal breast tissues (n = 8). Methylation data were statistically
correlated with clinical patient characteristics. All statistical
evaluations were performed with SPSS 14.0 software.
Results  DKK3  mRNA was downregulated in 71% (five of
seven) of breast cancer cell lines and in 68% of primary breast
carcinomas (27 of 40) compared with benign cell lines and
normal breast tissues, respectively. A DNA demethylating
treatment of breast cell lines resulted in strong induction of
DKK3 mRNA expression. In tumourous breast tissues, DKK3
mRNA downregulation was significantly associated with DKK3
promoter methylation (p < 0.001). Of the breast carcinomas,
61% (92 of 150) revealed a methylated DKK3  promoter,
whereas 39% (58 of 150) retained an unmethylated promoter.
Loss of DKK3 expression in association with DKK3 promoter
methylation (p = 0.001) was also confirmed at the protein level
(p < 0.001). In bivariate analysis, DKK3 promoter methylation
was not associated with investigated clinicopathological
parameters except patient age (p = 0.007).
Conclusions DKK3 mRNA expression and consequently DKK3
protein expression become frequently downregulated during
human breast cancer development due to aberrant methylation
of the DKK3 promoter. Since DKK3 is thought to negatively
regulate oncogenic Wnt signalling, DKK3 may be a potential
tumour suppressor gene in normal breast tissue.
Introduction
The mammalian Dickkopf genes (DKK) encode a class of
extracellular signalling molecules that control cell fate during
embryonic development and regulate tissue homeostasis in
adults [1,2]. Four DKK gene members have been identified so
far. DKK1, DKK2 and DKK4 antagonise canonical Wnt/β-cat-
enin signalling by interaction with LDL-receptor-related pro-
teins (LRP5 and LRP6) [3]. In contrast, DKK3  does not
DKK3: Dickkopf-3; FC: fold change; IRS: immunoreactivity score; JNK: c-Jun-kinase; LRP: LDL-receptor related protein; MSP: methylation-specific 
polymerase chain reaction; PCP: planar cell polarity pathway; RT-PCR: reverse transcription polymerase chain reaction; SD: standard deviation; 
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sequester LRPs or Wnt ligands [2,4,5]. Its function in antago-
nising nuclear β-catenin levels, designated as the hallmark of
an activated Wnt pathway often found in human tumour tis-
sues [6], has received conflicting reports [7-9]. Most evidence
suggest DKK3 exerts a tumour suppressive function by inhib-
iting a non-canonical Wnt signalling branch referred to as the
planar cell polarity (PCP) pathway. The PCP pathway is char-
acterised by the activation of c-Jun kinase (JNK) via recruit-
ment of small GTPases of the Rho/Rac family [10]. It results in
changes in cell adhesion, motility and polarity [11] rather than
interfering with the networks of proliferation and differentiation,
which is mediated by canonical Wnt/β-catenin signalling [6].
In agreement with its putative tumour-suppressive function
[9,12-14]DKK3 is commonly downregulated in human can-
cers such as lung cancer [15-17], renal clear cell carcinoma
[18], pancreatic cancer [19], leukaemia [20], prostate cancer
[7,21], bladder cancer [22], melanoma [23] and gastrointesti-
nal tumours [24]. In many of these diseases transcriptional
loss is tightly associated with methylation of the DKK3 pro-
moter [15,16,18,20-22,24], whereas in other malignancies
the cause of downregulation remains to be elucidated or is not
related to 5'-cytosine methylation [23]. A study on lung cancer
revealed that the rate of DKK3 methylation increased steadily
from normal lung tissue, to low-grade and high-grade atypical
adenomatous hyperplasia to invasive adenocarcinoma [25],
suggesting a potential role of DKK3 methylation in lung cancer
progression. In mouse cancer models, DKK3 has proved a
promising therapeutic agent capable of repressing tumour
progression, for example, in testicular germ cell cancer [14]
and prostate cancer [13]. More recently, a breast cancer
xenotransplantation model demonstrated that a single adeno-
viral-mediated intra-tumoural injection of a DKK3 expression
vector efficiently discontinued tumour growth, with the induc-
tion of apoptosis in these cells [26]. This suggests that DKK3
may have an important tumour-suppressive function that either
prevents tumour initiation or attenuates cancer progression.
Interestingly, loss of DKK3 expression was first observed in
numerous immortalised tumour-derived cell lines [27]. Immor-
talisation, that is escape from cellular senescence, is an early
event in malignant transformation [28], so DKK3 could act as
a tumour suppressor gene by mediating the effects of senes-
cence stimuli. In concordance with this hypothesis, DKK3
expression was found to be elevated in organs with predomi-
nantly growth-arrested post-mitotic cells, for example in the
heart and brain [29] and also in senescent prostate epithelial
cells [30].
However, to the authors' knowledge, a comprehensive study
on DKK3 gene regulation and its implication in breast cancer
has not yet been published. In our study we investigated
DKK3 mRNA expression, DKK3 protein expression and DKK3
promoter methylation in breast cell lines as well as in normal
and malignant primary breast tissues. Our results demonstrate
for the first time that DKK3 expression is frequently downreg-
ulated in human breast cancer as a consequence of aberrant
DNA methylation within the DKK3 gene promoter.
Materials and methods
Patient material
Nineteen matched tumour and normal tissue samples from
breast cancer patients and 131 tissue samples from breast
carcinomas were obtained from patients treated by primary
surgery for breast cancer at the Departments of Gynecology
at the University Hospitals of Aachen, Jena, Regensburg and
Düsseldorf, Germany, between 1991 and 2005. The selection
of cases was based on availability of tissue, and the sample
was recruited in a non-selective, consecutive manner. Female
patients presenting with unilateral, invasive breast cancer with
no individual breast cancer history were included in the study.
Exclusion criteria were: neo-adjuvant chemotherapy before
surgery; presentation with secondary breast cancer; or peritu-
mourous carcinoma in situ present in the tumour sample.
Patient characteristics are shown in Table 1.
All patients gave informed consent for retention and analysis
of their tissue for research purposes and the Institutional
Review Boards of the participating centres approved the
study.
Tumour histology was determined according to the criteria of
the World Health Organization [31], while disease stage was
assessed according to International Union Against Cancer
[32]. Tumours were graded according to Bloom and Richard-
son, as modified by Elston and Ellis [33]. After surgery, tumour
material was immediately snap-frozen in liquid nitrogen. Sec-
tions stained with haematoxylin and eosin were prepared for
assessing the percentage of tumour cells; only samples con-
taining more than 70% tumour cells were selected. Samples
were dissolved in lysis buffer followed by DNA isolation using
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer's recommendations.
Breast cell lines
The cancerous breast cell lines BT20, Hs578T, MCF7, MDA-
MB231, SKBR3, T47D and ZR75-1 and the non-cancerous
lines HMEC and MCF12A were obtained from the American
Type Culture Collection (ATCC) (Rockville, MA, USA) and cul-
tured under recommended conditions.
RNA expression analysis
RNA isolation, RT-PCR and realtime PCR were performed as
previously described [34]. To ensure experiment accuracy, all
quantitative measurements were performed in triplicate.
Intron-spanning primer sequences and cycling conditions are
given in Table 2.
Bisulphite-modification and methylation-specific PCR
About 1 μg of genomic DNA was bisulphite-modified using the
EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA)Available online http://breast-cancer-research.com/content/10/5/R82
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according to the manufacturer's recommendations. Methyla-
tion-specific PCR (MSP) was performed as previously
described [34]. Primers and cycling conditions are listed in
Table 2. Specificity of MSP primers in detecting the DKK3
methylation status were demonstrated using universal unmeth-
ylated and universal polymethylated DNA as a template (Epi
Tect Control DNA Set; Qiagen, Hilden, Germany).
Table 1
Demographic and clinical patient characteristics of primary breast carcinomas (n = 150)
Variable Categorisation n1 %
Clinicopathological factors
Age at diagnosis
median: 57 years (range 28 to 86 years)
<57 years 74 49.3
= 57 years 76 50.7
Tumour size2
pT1 59 39.3
pT2 70 46.7
pT3 8 5.3
pT4 10 6.7
pTx 3 2.0
Lymph node status2
pN0 72 48.0
pN1 to 3 71 47.3
PNx 7 4.7
Histological grade
G1 13 8.7
G2 75 50.0
G3 62 41.3
Histological type
Ductal 122 81.3
Lobular 19 12.7
Other 9 6.0
Immunohistochemistry
Oestrogen receptor
Negative (IRS3 0 to -2) 47 31.3
Positive (IRS 3 to 12) 98 65.3
n.a. 5 3.3
Progesterone receptor
Negative (IRS3 0 to 2) 51 34.0
Positive (IRS 3 to 12) 94 62.7
n.a. 5 3.3
1Only female patients with unilateral invasive breast cancer were included. 2According to International Union Against Cancer: TNM Classification 
of Malignant Tumours [32].3IRS = immunoreactivity score [35]. n.a. = not available.Breast Cancer Research    Vol 10 No 5    Veeck et al.
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5-aza-2'-deoxycytidine and trichostatin A treatment
DNA demethylating treatment of breast cancer cell lines was
performed with 5-aza-2'-deoxycytidine as described else-
where [34], modified by the addition of 300 nM of the histone
deacetylase inhibitor trichostatin A (Sigma-Aldrich, Deisen-
heim, Germany) on day three (incubation for 24 hours). Drug
concentrations were adjusted in advance to warrant viability
and replication of all cell lines.
Immunohistochemistry
Formalin-fixed, paraffin-embedded 2 μm tissue sections were
subjected to immunostaining using the Advance Kit (Dako,
Hamburg, Germany) following the manufacturer's instructions.
Antigen retrieval was performed by pre-treatment with citrate
buffer (pH 7) in a microwave oven (20 minutes at 200 W).
Sections were incubated for 30 minutes with the primary anti-
body (AP1523a, Abgent, San Diego, CA, USA; 1:50), washed
and incubated for 10 minutes with the secondary antibody
(biotinylated polylink; Dako, Hamburg, Germany). Diaminoben-
zidin (Dako, Hamburg, Germany) was used for antibody detec-
tion. An experienced breast cancer pathologist (N.B.) scored
the immunohistochemical staining according to the scoring
system suggested by Remmele and Stegner [35]. The tissue
specimens for immunohistochemical analysis are character-
ised in Table 3.
Table 2
Oligonucleotide primers used in the study
Sequence (5' to 3') TA [°C] Primer [nM] Cycles Product size (bp)
RT-PCR
GAPDH Forward: TGGTCACCAGGGCTGCTT
59 400 35 510
Reverse: GTCTTCTGGGTGGCAGTGAT
DKK3 Forward: AAGGCAGAAGGAGCCACGAGTGC
59 400 35 182
Reverse: GGCCATTTTGGTGCAGTGACCCCA
Semiquantitative realtime PCR
GAPDH Forward: ATGGCCAGCGGGAAGAC
60 500 40 289
Reverse: ATGGCCAGCGGGAAGAC
DKK3 Forward: ACAGCCACAGCCTGGTGTA
60 400 40 123
Reverse: CCTCCATGAAGCTGCCAAC
Methylation-specific PCR
DKK3 unmethylated Forward: TTAGGGGTGGGTGGTGGGGT
58 320 34 126
Reverse: CTACATCTCCACTCTACACCCA
DKK3 methylated Forward: GGGCGGGCGGCGGGGC
58 320 34 120
Reverse: ACATCTCCGCTCTACGCCCG
TA = annealing temperature.Available online http://breast-cancer-research.com/content/10/5/R82
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Statistical evaluations
Statistical analyses were completed using SPSS 14.0 (SPSS,
Chicago, IL, USA). Differences were considered significant
when p < 0.05. A non-parametric Mann-Whitney U-test and a
Kruskal-Wallis test were applied to examine expression levels
among normal tissues, DKK3  unmethylated tumours and
DKK3 methylated tumours. A student's t-test was applied on
the expression of paired normal and tumour samples. To study
statistical associations between clinicopathological factors
and DKK3 methylation status contingency tables and a two-
sided Fisher's exact test were used.
Results
Differential DKK3 mRNA expression in breast cell lines
To start our analysis of DKK3 expression in breast cancer
patients we analysed mRNA expression in non-malignant and
malignant breast cell lines using realtime PCR. Strong DKK3
expression could be detected in non-malignant HMEC and
MCF12A cells (Figure 1a) exhibiting expression levels compa-
rable with human placental tissue, which is known to abun-
dantly express DKK3 [22]. Among the malignant cell lines,
Hs578T and SKBR3 cells revealed abundant DKK3 mRNA
levels comparable with benign breast cells. In five further
breast cancer cell lines (BT20, MCF7, MDA-MB231, T47D
and ZR75-1) DKK3 expression was substantially reduced.
Methylation of the DKK3 promoter in breast cell lines
Aberrant promoter hypermethylation of tumour suppressor
genes during carcinogenesis is an effective mechanism result-
ing in downregulation and functional inactivation of these
genes [36,37]. Knowing that DKK3 expression was downreg-
ulated in most malignant breast cell lines we performed pro-
moter methylation analysis in these cells. By using MSP [38]
we found a methylated DKK3 promoter sequence in all cell
lines showing reduced DKK3 expression, BT20, MCF7, MDA-
MB231, T47D and ZR75-1 (Figure 1b). In contrast to this, all
DKK3 expressing cell lines (HMEC, MCF12A, Hs578T and
SKBR3) as well as human placental tissue lacked DKK3 pro-
moter methylation in the analysed promoter region.
In vitro demethylation of the DKK3 promoter
To prove a direct association of DKK3 promoter methylation
with loss of DKK3 mRNA expression we treated seven breast
cell lines sequentially with the DNA-methyltransferase inhibitor
5-aza-2'-deoxycytidine and the histone deacetylase inhibitor
trichostatin A. Subsequently, we determined DKK3 promoter
methylation and DKK3 mRNA expression before and after the
drug treatment. MSP analyses after the treatment (Figure 2a)
confirmed that promoter demethylation had occurred in all
methylated cell lines by the appearance and enhancement of
signals indicative of unmethylated DNA sequences. Those cell
lines initially bearing a methylated DKK3 promoter showed
Table 3
Immunohistochemical analysis of DKK3 protein expression in breast cancer samples (n = 16) in relation to clinicopathological 
parameters
Age Size1 (pT) Node status1 (pN) Grade Histology ER2 PR2 DKK3 methylation DKK3 IRS tumour3 DKK3 IRS normal4
49 1 0 3 IDC - - - 9 12
85 2 1 3 IDC - - n.a. 3 n.a.
69 2 1 2 ILC - - - 9 12
82 3 1 3 IDC - - + 6 n.a.
45 1 1 3 IDC - - + 4 12
60 3 0 3 IDC - - n.a. 8 n.a.
61 1 0 2 IDC - - + 0 n.a.
72 1 0 2 IDC - - n.a. 4 n.a.
44 1 1 3 IDC - - - 12 12
86 2 n.a. 3 IDC - - - 8 n.a.
60 1 1 3 IDC + - + 2 9
66 1 0 2 IDC + + + 3 n.a.
54 2 0 3 IDC + - + 6 12
83 1 0 2 IDC + + - 9 n.a.
79 2 0 3 IDC + + - 8 12
62 4 1 3 IDC + - + 3 9
1According to International Union Against Cancer: TNM Classification of Malignant Tumours [32]. 2According to Remmele and Stegner [35]. 
3According to Remmele and Stegner [35] as a continuous variable. 4Matched normal breast epithelial tissue. IRS = immunoreactivity score. IDC = 
invasive ductal carcinoma. ILC = invasive lobular carcinoma. n.a. = not available.Breast Cancer Research    Vol 10 No 5    Veeck et al.
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elevated  DKK3  mRNA expression after treatment (BT20,
MCF7, MDA-MB231, T47D and ZR75-1; Figure 2b), whereas
no DKK3 mRNA gain was achieved in unmethylated MCF12A
and only a marginal DKK3 mRNA gain in SKBR3 cells. The
induction of DKK3 mRNA transcription after the treatment as
determined by realtime PCR ranged from 4.7-fold to 29-fold
higher than in originally methylated breast cancer cells.
Differential DKK3 mRNA expression in primary breast 
carcinomas
DKK3 mRNA expression in primary breast tissues was then
examined by realtime PCR. In the first step, 19 pairs of breast
carcinoma tissues and corresponding normal breast tissue
were analysed. A significant downregulation of DKK3 mRNA
expression in tumour tissue compared with its adjacent normal
tissue was detected in 14 (74%) of the 19 pairs (Figure 3a),
as defined by an expression fold change of two or more (FC2).
To further support this data set we analysed 40 additional
breast carcinomas with no corresponding normal breast tissue
and referred each individual DKK3 mRNA expression level to
the mean DKK3 expression of the previously analysed 19 nor-
mal breast tissues (Figure 3b). The frequency of DKK3 mRNA
downregulation measured in this tumour cohort (27 of 40,
68% by FC2) is in good agreement to the result achieved with
the 19 matched pairs. Therefore downregulation of DKK3
mRNA in breast cancer is considered to affect about 70% of
patients.
Figure 1
DKK3 mRNA expression and DKK3 promoter methylation analysis in  breast cell lines DKK3 mRNA expression and DKK3 promoter methylation analysis 
in breast cell lines. (a) DKK3 mRNA expression is differentially 
expressed in breast cell lines. Non-cancerous cell lines (HMEC and 
MCF12A) and cancerous breast cell lines (Hs578T, SKBR3, BT20, 
MCF7, MDA-MB231, T47D and ZR75-1) were analysed by realtime 
PCR and related to DKK3 mRNA expression in human placental tissue 
(set to 1). Grey bars = samples expressing abundant DKK3 mRNA; 
black bars = samples showing strong downregulation of DKK3 expres-
sion. (b) Hypermethylation of the DKK3 promoter in breast cell lines. 
Methylation specific PCR (MSP) was performed with bisulphite-treated 
DNA from benign and malignant breast cell lines. DNA bands in lanes 
labelled with U indicate PCR products amplified with primers recognis-
ing unmethylated DKK3 promoter sequence. DNA bands in lanes 
labelled with M represent amplificate generated with methylation-spe-
cific primers; water served as 'no template control' (NTC). MSP con-
trols demonstrate the specificity of the DKK3 primers used. Universal 
poly-methylated bisulphite-converted DNA (UMD) exclusively yields 
amplification products with primers specific to methylated DKK3 pro-
moter sequence; universal unmethylated bisulphite-converted DNA 
(UUD) yields exclusive amplification products with primers recognising 
the unmethylated DKK3 promoter sequence.
Figure 2
DKK3 mRNA expression after in vitro DNA demethylation DKK3 mRNA expression after in vitro DNA demethylation. (a) In 
vitro demethylation of the DKK3 promoter. Methylation specific PCR of 
seven breast cell lines was performed with DNA from cells either 
untreated (-) or treated with 1 μM 5-aza-2'-deoxycytidine (DAC) and 
300 nM trichostatin A (TSA) (+). (b) Re-expression of DKK3 mRNA in 
breast cell lines after treatment with DAC/TSA. All cell lines initially 
exhibiting low DKK3 mRNA restored expression of DKK3 compared 
with the untreated control cells. Induction level (fold change) of DKK3 
mRNA expression was determined by realtime PCR.Available online http://breast-cancer-research.com/content/10/5/R82
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DKK3 promoter methylation in primary breast 
carcinomas
To address the question of whether DKK3 promoter methyla-
tion occurs in primary breast carcinomas, we analysed 150
mammary tumour samples by MSP. Corresponding normal
breast tissue was available for 19 tumours. In total, 92 of 150
tumours (61.3%) revealed DKK3  promoter methylation (for
example, #7 in Figure 4) whereas in 58 of 150 tumours
(38.7%) the DKK3  promoter was unmethylated. In these
cases, MSP amplification signals were obtained exclusively in
the U-reaction (for example, #5 in Figure 4). Of the normal
breast tissues, only a single sample (5.3% of 19 samples)
gave a very weak methylation signal (data not shown) in con-
trast to all other normal tissues that lacked DKK3 promoter
methylation. As an additional control that infiltrating immune
cells do not contribute to methylation signals in mammary
tumours, bisulphite-converted DNA from human peripheral
blood lymphocytes were assayed and revealed an unmethyl-
ated DKK3 promoter, consistent with results from a previous
study [39].
Correlation of DKK3 promoter methylation with loss of 
DKK3 mRNA expression
For all breast carcinoma samples analysed for DKK3 mRNA
expression (n = 59) we determined the DKK3 promoter meth-
ylation status at the same time. Thus, we were able to directly
compare DKK3 methylation and mRNA expression in primary
human breast carcinomas. A boxplot (Figure 5) illustrates the
distribution and medians of DKK3 RNA expression among
normal breast tissues, DKK3  unmethylated tumours and
DKK3  methylated tumours. The median DKK3  expression
level (exp) of unmethylated tumours (exp = 0.87; FC = 1.2)
was comparable with that of normal breast tissues (set to exp
= 1). In contrast, DKK3 methylated tumours showed a signifi-
cant mRNA downregulation (exp = 0.17; FC = 5.9) compared
with DKK3 unmethylated tumours and normal breast tissue
(global p < 0.001).
Differential DKK3 protein expression in primary breast 
carcinomas
Immunohistochemical staining was used to investigate DKK3
protein expression in normal (n = 8) and malignant (n = 16)
Figure 3
DKK3 mRNA expression analysis in primary breast carcinomas DKK3 mRNA expression analysis in primary breast carcinomas. (a) Realtime PCR of DKK3 mRNA expression in 19 matched pairs (normal vs. 
tumour). Arrowheads indicate downregulation in the tumour by an expression fold change of more than two (FC2). (b) Relative DKK3 mRNA expres-
sion in 40 additional breast cancer specimens. Mean expression of 19 normal breast tissues (N) was set to 1. Based on a FC2, grey bars represent 
tumour specimens (T) showing normal expression, black bars represent tumour specimens with reduced DKK3 mRNA expression.Breast Cancer Research    Vol 10 No 5    Veeck et al.
Page 8 of 11
(page number not for citation purposes)
breast tissues. DKK3 was strongly expressed in non-malignant
luminal and basal epithelial cells, achieving a mean (sd) immu-
noreactivity score (IRS) [34] of 11.3 (1.4) (Figure 6a) and a
median IRS of 12 (range 9 to 12). DKK3 protein was not
detectable in stromal cells in the normal breast tissue. Of the
breast carcinomas, four of 16 (25%) revealed abundant DKK3
protein expression (IRS = 9 to 12; Figure 6b) in contrast to
seven of 16 tumours (44%), which showed partial loss (IRS =
4 to 8; Figure 6c), and five of 16 tumours (31%) with substan-
tial loss of DKK3 protein (IRS = 0 to 3; Figure 6d and Table 3).
The mean protein staining intensity in breast carcinomas was
determined to have an IRS of 5.9 (3.3) and the median to have
an IRS of 6 (range 0 to 12). DKK3 expression levels in the
tumour and normal tissue groups were shown to be signifi-
cantly different (p = 0.002; U-test), and DKK3 protein was also
differentially expressed within the eight matched pairs (p <
0.001; t-test). As a continuous variable, a lower IRS in breast
carcinoma was significantly associated with the presence of
DKK3 promoter methylation (p = 0.001; Fisher's exact test).
Association of DKK3 promoter methylation with 
clinicopathological factors
For descriptive data analysis clinicopathological patient char-
acteristics were correlated with the DKK3 promoter methyla-
tion status. In a bivariate analysis, DKK3 promoter methylation
was significantly associated with advanced patient age at
diagnosis (p = 0.007). Furthermore, DKK3 promoter methyla-
tion was not associated with tumour size, lymph node status,
histological grade, histological type, and oestrogen receptor
or progesterone receptor positivity (data not shown).
Discussion
It was previously reported that expression of the putative Wnt
antagonist DKK3 was downregulated in several tumour enti-
ties as a consequence of epigenetic DNA modification
[15,16,18,20-22,24]. Our study is the first to analyse DKK3
gene regulation in human breast cancer. Malignant breast cell
lines showed strong reduction of DKK3 mRNA in association
Figure 4
DKK3 promoter methylation analysis in primary breast carcinomas DKK3 promoter methylation analysis in primary breast carcinomas. Methylation specific PCR results from 10 representative matched pairs of 
primary breast tumour (T) and corresponding normal breast tissue (N) are shown. DNA from human placenta (Plc) as well as from peripheral blood 
lymphocytes (Lyc) reveals an unmethylated DKK3 promoter. DNA from breast carcinoma cell line BT20 served as positive control. NTC = no tem-
plate control.
Figure 5
Correlation analysis of DKK3 promoter methylation with DKK3 mRNA  expression in primary breast carcinomas Correlation analysis of DKK3 promoter methylation with DKK3 
mRNA expression in primary breast carcinomas. Tumours that are 
unmethylated in the DKK3 promoter express DKK3 mRNA comparable 
with DKK3 mRNA expression normal breast tissue, whereas in DKK3 
methylated tumours DKK3 mRNA expression is significantly reduced. 
Horizontal lines = group medians; boxes = 25 to 75% quartiles, range, 
peak and minimum.Available online http://breast-cancer-research.com/content/10/5/R82
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with DKK3 promoter methylation. Consistently, DKK3 mRNA
expression was induced after promoter DNA demethylation in
these cells. In primary breast carcinomas, DKK3  mRNA
expression was downregulated in 68% of invasive tumours
with significant association with methylation of the DKK3 gene
promoter (p < 0.001). The total frequency of DKK3 methyla-
tion was 61% in breast carcinomas, whereas corresponding
normal breast tissues were unaffected by this epimutation. We
further showed that a loss of DKK3 protein in breast carcino-
mas is also associated with DKK3 promoter methylation (p =
0.001) whereas protein expression is abundant in epithelial
cells of the normal breast. In summary, our data demonstrate
for the first time that promoter methylation-mediated downreg-
ulation of DKK3 expression is a frequent and tumour-related
epigenetic alteration in the development of human breast
cancer.
The implication of aberrant canonical Wnt/β-catenin signalling
in the pathogenesis of human cancer has become widely
accepted [40]. Its oncogenic effect is mediated by uncon-
trolled activation of target genes that for example, enhance cell
proliferation, such as c-myc and cyclin D1. In breast cancer,
several genes encoding inhibitors of canonical Wnt/β-catenin
signalling have been reported to be frequently hypermethyl-
ated, for example, SFRP1 [34,41], SFRP2 [42], SFRP5 [43],
WIF1 [44] and DKK1 [42]. We suggest that disruption of a
non-canonical Wnt signalling branch, the PCP pathway, may
also be implicated in human carcinogenesis by pathologically
altering the networks of cellular adhesion, motility and cell
polarity, because it has been shown that expression of the
putative PCP pathway inhibitor DKK3 is commonly downreg-
ulated in malignant tissues. As a consequence, loss of DKK3
may promote hyperactivation of the PCP pathway, thereby
potentially enhancing tumour aggressiveness.
Recent in vivo experiments support a hypothesis that the loss
of DKK3 expression promotes an aggressive cancer pheno-
type. In a mouse model, DKK3 proved to be a promising ther-
apeutic agent to significantly inhibit tumour growth in testicular
germ cell cancer [14]. In an orthotopic prostate cancer model
a similar treatment resulted in tumour regression, decreased
metastasis and prolonged survival of the host [13]. The most
recent findings from a breast cancer study revealed that DKK3
not only attenuates tumour growth in a xenotransplantation
mouse model, it also re-sensitised multidrug-resistant MCF7/
ADR cells to doxorubicin treatment in a JNK-c-Jun dependent
manner [26]. This highlights its potential utility as a gene ther-
apeutic agent in human breast cancer. Our study adds impor-
tant information to this aspect, because it so far remained
unknown if methylation-mediated loss of DKK3  expression
also occurred in primary breast cancer, and, if so, how many
patients were affected by this epimutation. We have shown
that a large proportion (61%) of breast cancer patients have
DKK3 promoter methylation in the carcinoma tissue, leading
to a functional inactivation of the tumour-protective protein.
Therefore, we conclude that a potential gene therapeutic treat-
ment with DKK3 might be of benefit for a large target popula-
tion of breast cancer patients.
In contrast to other studies, DKK3 promoter methylation in our
cohort was not associated with clinicopathological factors
indicative of a progressive cancer subtype, such as tumour
size, node status or histological grade. The existence of such
an association has been demonstrated in prostate cancer
[7,12], in which expression of DKK3 was predominantly lost in
high-grade prostatic tumours. Moreover, siRNA-mediated
downregulation of DKK3 expression in prostate epithelial cells
disrupted acinar morphogenesis [7], which taken with its prev-
alent expression in growth-arrested cells suggests a functional
role of DKK3 in post-mitotic tissue differentiation processes.
Whether DKK3 is also involved in maintaining glandular mor-
Figure 6
DKK3 protein expression in primary breast carcinomas as determined  by immunohistochemical staining DKK3 protein expression in primary breast carcinomas as deter-
mined by immunohistochemical staining. (a) Normal mammary tis-
sue without (left) and with application (right) of DKK3 antibody. 
Abundant DKK3 protein expression is detectable in luminal and basal 
epithelial cells. (b) Breast carcinoma with unmethylated DKK3 pro-
moter reveals abundant DKK3 protein expression. (c) and (d) Breast 
carcinomas with a methylated DKK3 promoter exhibit substantial loss 
of DKK3 protein expression. Original magnifications are given in upper 
right-hand corner.Breast Cancer Research    Vol 10 No 5    Veeck et al.
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phology in the normal mammary gland will be elucidated in a
further study.
In human breast cancer, hypermethylation of Wnt antagonist
genes was reported to be of clinical relevance. Both SFRP1
and SFRP5 methylation were shown to occur frequently and
be tumour specific with a strong association to poor clinical
patient outcome [34,43]. An impact of DKK3 promoter meth-
ylation on cancer patient survival has been repeatedly found. It
was shown to be associated with reduced disease-free sur-
vival in acute lymphoblastic leukaemia [20], and also with
shorter overall survival in kidney cancer [45] and lung cancer
[46]. Due to its functional properties as a potential tumour sup-
pressor in human cancers including breast cancer [26],
together with the finding that DKK3 methylation is a significant
prognostic factor in three human malignancies, we speculate
that DKK3 methylation might also bear prognostic power in
breast cancer. This hypothesis is currently being approached
in our laboratory in a further study.
In summary, we demonstrate for the first time that the Wnt
antagonist gene DKK3 is a frequent target of epigenetic inac-
tivation in human breast cancer, leading to downregulation of
DKK3 mRNA and DKK3 protein expression in tumourous tis-
sues. These results suggest a causative implication of DKK3
in the development of human breast cancer. Since DKK3 is
believed to negatively regulate Wnt signalling, these results
underline the pivotal role of a deregulated Wnt signalling path-
way commonly found in this disease.
Conclusion
This study shows that the putative Wnt antagonist DKK3 is
frequently downregulated in human breast cancer due to pro-
moter methylation, whereas it is abundantly expressed and
unmethylated in normal breast cell epithelium. Since promoter
methylation is a primary cause to functionally inactivate tumour
suppressor genes, DKK3 may act as a tumour suppressor in
the human mammary gland. DKK3 is believed to particularly
regulate non-canonical Wnt signalling. Therefore, we con-
clude that disruption of this Wnt pathway branch may add fur-
ther tumour growth advantages to those already conferred by
canonical Wnt/β-catenin signalling.
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